Literature DB >> 9681802

Prevalence and disease experience rates in Korean physicians.

J J Kim1, S D Kim, K H Meng, Y O Ahn, Y T Yum, H C Oh, D B Lee, S I Lee, B Y Chun, J S Choi.   

Abstract

This study aimed to find out the morbid status of Korean physicians living in Korea, as one part of a feasibility study on the Korean physician cohort. It was performed by mail survey using a self-administered questionnaire from Jan. 1, 1995 through Dec. 31, 1995. Study subjects were 21,552 including 17,877 (81.1%) males and 3,384 (15.5%) females. Person based prevalence rate of disease was 17.7% (18.3% for males and 13.8% for females) with the rate increasing with age. The disease group showing the highest prevalence rate was circulatory diseases (5.16%) for males, and respiratory disease (3.13%) for females. The individual disease showing the highest prevalence rates was hypertension (3.77%) for males and allergic rhinitis (2.25%) for females. The person based disease experience rate was 36.2% (36.9% for males, 32.7% for females) with the rate increasing with age. The disease group showing the highest disease experience rate was digestive disease for both sexes (10.05% for males, 7.42% for females). Individual disease showing the highest disease experience rate was hypertension (5.00%) for males and allergic rhinitis (4.08%) for females. There were different ranks of both prevalence and disease experience rate depending on age in both sexes.

Entities:  

Mesh:

Year:  1998        PMID: 9681802      PMCID: PMC3054498          DOI: 10.3346/jkms.1998.13.3.247

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  2 in total

1.  A comparison of response rate and time according to the survey methods used: a randomized controlled trial.

Authors:  Sang-Wook Yi; Jae Seok Hong; Heechoul Ohrr; Jee Jeon Yi
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

Review 2.  The current status of asthma in Korea.

Authors:  Sang Heon Cho; Heung Woo Park; Daniel M Rosenberg
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.